Company Overview and News

 
Sakthi Sugars Limited - Press Release

10h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Sakthi Sugars Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Government should look to build 5 mt buffer of sugar stock: Sakthi Sugars

2018-03-21 moneycontrol
Sugar stocks will be in focus today as the government has scrapped export duty of raw and refined sugar to boost shipments. In an interview to CNBC-TV18, M Manickam, Executive VC of Sakthi Sugars spoke at length about the sector.

 
No more SAP for TN sugar mills

2018-03-15 thehindubusinessline
Shares of Tamil Nadu-based sugar producers such as EID Parry, Ponni Sugars (Erode), Rajshree Sugars and Chemicals, Sakthi Sugars and Thiru Arooran Sugars may see buying interest, as the TN government has decided to move away from State Advisory Price over and above the fair and remunerative price for sugarcane. In the Budget speech on Thursday, the Finance Minister said the state has decided to switch over to the revenue share price fixation model.

 
Govt is taking steps to stabilise the sugar price: Sakthi Sugars

2018-03-06 moneycontrol
Sugar production is already on the higher side and at ISMA's board meet on March 7 it could head further north.

 
Market Update: CNX Metal outshines led by JSPL, Tata Steel; Vedanta top gainer; IndusInd, Yes Bank up 2%

2018-03-06 moneycontrol
The Indian benchmark indices were trading on a positive note on Tuesday morning with the Nifty gaining 68 points at 10,462 while the Sensex jumped 233 points.

 
Sakthi Sugars Limited - Updates

2018-02-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Sakthi Sugars Limited - Financial Result Updates

2018-02-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Global cues, banks drag Sensex 310 pts, Nifty below 10,700; midcaps recover sharply

2018-02-05 moneycontrol
Investors sentiment remained weak on Monday as benchmark indices extended sell-off for the fifth consecutive session, dented by global weakness on worries that US inflation could rise faster than expectations.

 
 
Market Update: Nifty Pharma outperforms with DRL top Nifty gainer; TCS falls 3%, SBI most active

2017-12-14 moneycontrol
The Indian benchmark indices on Thursday afternoon were trading on a negative note with the Nifty down 9 points or 0.09 percent while the Sensex shedding 46 points and was trading at 33012.

 
Market Update: TCS, UPL fall 2%, Glenmark Pharma hits 52-week low; Tata Comm, RIL most active

2017-12-14 moneycontrol
The Indian benchmark indices on Thursday afternoon were trading on a negative note with the Nifty up 19 points or 0.19 percent while the Sensex shedding 80 points and was trading at 32972.

 
Market Update: SBI, PNB, YES Bank up 2% as Bank Nifty outperforms; Hero Moto, Wipro top losers

2017-12-05 moneycontrol
The Indian benchmark indices on Tuesday afternoon were still trading on a negative note with the Nifty up 1 point or 0.01 percent while the Sensex shed 25 points and was trading at 32838.

 
Market Update: RIL, Bharti Airtel top Nifty gainers; Eicher Motors down over 2%, Infosys most active

2017-12-05 moneycontrol
The Indian benchmark indices on Tuesday afternoon were still trading on a negative note with the Nifty down 42 points or 0.42 percent while the Sensex shed 141 points and was trading at 32727.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

23h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...